NU 670 Unit 8 regimen lifecycle dossier example

Regimen Lifecycle Dossier: Three Years of Olanzapine for One Woman With Schizophrenia, From the Choice of Agent to a Decision About Its Metabolic Cost

Student Name

Department of Nursing, Herzing University

NU 670: Advanced Psychopharmacology and Health Promotion

Instructor Name

March 11, 2026

Regimen Lifecycle Dossier: Three Years of Olanzapine for One Woman With Schizophrenia, From the Choice of Agent to a Decision About Its Metabolic Cost

1. The Person and the Regimen

The person in this dossier, Ms. R., is a composite woman now 38, diagnosed with schizophrenia eight years ago. She has taken olanzapine for three years, currently 15 mg at bedtime, together with sertraline 100 mg for a depressive episode, lisinopril for blood pressure, and metformin 500 mg twice a day, added a year ago when her glucose crept up. She works part-time at a grocery store and lives with her sister. This dossier traces the regimen from the reasons it was chosen to the decision now facing her and her prescriber.

2. Why Olanzapine Was Defensible

Before olanzapine, Ms. R. took two other second-generation antipsychotics. Risperidone controlled her hallucinations but raised her prolactin, stopping her periods, and she stopped taking it. Aripiprazole caused akathisia severe enough that she could not sit through a shift, and she relapsed after stopping it, with a two-week hospitalization. At that point, the choice of olanzapine rested on three grounds: its effectiveness, since in a large comparative trial it was associated with the lowest rate of discontinuation for any cause among the drugs studied (Lieberman et al., 2005); its low rate of akathisia and modest effect on prolactin, given the effects that had ended her earlier trials; and her own priority, stated at the time, to stay out of the hospital and keep her job. The known cost, weight gain and metabolic effects, was discussed and accepted, with a plan to monitor.

3. How Response Was Measured

Response was measured with the Brief Psychiatric Rating Scale at each visit for the first six months and every three months since. Her score fell from 58 at the start of olanzapine to 32 at eight weeks and has stayed between 28 and 34. She has had no hospitalizations in three years, has kept her job, and reports that her hallucinations are rare and manageable. By the measures that mattered to her and to her treatment team, the regimen has worked.

4. What Monitoring Returned

Monitoring followed the clinic's metabolic protocol. The results over three years:

5. Reading the Monitoring Results

Her weight has risen 11 kg, about 16% of her baseline, well past the 5% threshold at which the protocol calls for review, and the review has happened twice: metformin was added at one year, and weight gain slowed afterward. Her glycated hemoglobin is in the prediabetes range and still rising slowly; her triglycerides have risen steadily. Her cardiovascular risk is further raised by smoking a pack a day. The binding profile of olanzapine predicts these effects, and they are among the reasons she has recently mentioned wanting to lose weight.

A recent episode showed how the regimen interacts with the rest of her life. An urgent care prescription for ciprofloxacin, an inhibitor of the enzyme that clears olanzapine, left her unusually drowsy; the antibiotic was changed. And she plans to quit smoking next month, which is likely to raise her olanzapine levels as the induction of that enzyme wears off.

6. The Decision Now

Three options were discussed with Ms. R. and her sister. First, continue olanzapine with more intensive metabolic management: increase metformin toward 1,000 mg twice daily, which a meta-analysis found reduced antipsychotic-associated weight gain (de Silva et al., 2016), join the clinic's healthy living group, and reduce olanzapine to 12.5 mg after her quit date if she becomes drowsier. Second, switch to an agent with lower metabolic risk. In a randomized trial of switching from olanzapine, quetiapine, or risperidone to aripiprazole, switching improved some metabolic measures, but more of those who switched stopped their assigned treatment early (Stroup et al., 2011). Aripiprazole has already caused her disabling akathisia, and the other lower-risk options carry their own tradeoffs. Third, continue unchanged, which the rising glucose and triglycerides make hard to justify.

Ms. R. chose the first option. Her reasoning was that three years without hospitalization is the most important thing she has, and that she would rather work hard on weight than risk a relapse. The plan sets explicit conditions for revisiting the decision: if her glycated hemoglobin reaches 6.5%, or her weight rises further over the next six months despite the higher metformin dose, a switch will be discussed again, with the specific alternative chosen to avoid akathisia.

Coordination With Primary Care

The metabolic side of the regimen is shared with Ms. R.'s primary care clinician, who manages her blood pressure and now her prediabetes. After this visit, the psychiatric clinic sent a note stating what it would do, increase metformin, refer to the healthy living group, and watch for changes in olanzapine levels after she quits smoking, and what it asked primary care to do: consider a statin given her rising triglycerides, smoking, and prediabetes, and support the quit attempt with varenicline or nicotine replacement. Neither clinic can manage this regimen alone. The psychiatric prescriber holds the decision about the antipsychotic, and the primary care clinician holds the treatment of the cardiovascular risk it adds, and each needs to know what the other is doing. Ms. R. asked that both clinics share results through the patient portal so that she could see them in one place, and the two clinics agreed to copy each other on every metabolic result for the next year.

7. What the Dossier Shows

The regimen's life so far has a clear logic. The agent was chosen after two others failed for reasons that olanzapine was unlikely to repeat. Response was measured and has been strong. Monitoring found the expected metabolic cost, and the response to it, metformin, slowed but did not stop it. The decision now weighs a proven benefit against a growing cost, and the person taking the drug has made that choice with the evidence in front of her and conditions for changing course written down. The next review is in three months, two weeks after her quit date.

References

de Silva, V. A., Suraweera, C., Ratnatunga, S. S., Dayabandara, M., Wanniarachchi, N., & Hanwella, R. (2016). Metformin in prevention and treatment of antipsychotic induced weight gain: A systematic review and meta-analysis. BMC Psychiatry, 16, Article 341. https://doi.org/10.1186/s12888-016-1049-5

Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J., & Hsiao, J. K. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353(12), 1209-1223. https://doi.org/10.1056/NEJMoa051688

Stroup, T. S., McEvoy, J. P., Ring, K. D., Hamer, R. H., LaVange, L. M., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Nussbaum, A. M., & Lieberman, J. A. (2011). A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of antipsychotics for metabolic problems (CAMP). American Journal of Psychiatry, 168(9), 947-956. https://doi.org/10.1176/appi.ajp.2011.10111609